Research programme: immunomodulators - Cytune Pharma

Drug Profile

Research programme: immunomodulators - Cytune Pharma

Alternative Names: CYP 0150; CYP 0150 (RLI); IL-15-IL-15 receptor α fusion protein; Interleukin-15-interleukin-15 receptor alpha fusion protein; RLI; RLI 15

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytune Pharma
  • Class Recombinant proteins
  • Mechanism of Action Immunostimulants; Interleukin-15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer; Malignant melanoma

Most Recent Events

  • 28 Nov 2017 Preclinical development is ongoing in France (9227911; Cytune Pharma pipeline, November 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France (Parenteral, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in France (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top